Uremic Pruritus - Pipeline Insight, 2024

This “Uremic Pruritus Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Uremic Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Uremic Pruritus Understanding

Uremic Pruritus: Overview

Uremic Pruritus, also known as chronic kidney disease- associated pruritus (CKD-aP) is more of a symptom associated with advanced or end-stage renal disease that adversely affects the quality of life of patients. It has been reported that more than 40% of people undergoing hemodialysis experience uremic pruritus.

Symptoms
Symptoms associated with uremic pruritus are the daily bouts of itching that worsen at night and may hinder sleep. The itch may mostly be localized to one part of the body such as head, back, abdomen, and/or arms. The skin may look normal or present with xerosis marked with multiple sores or marks.

Diagnosis
Uremic pruritus is diagnosed as the itch directly related to kidney disease and with the absence of any other comorbid conditions to associate with the itching. Uremic pruritus may have variable presentation, which may be difficult to diagnose.

Treatment
The treatment of uremic pruritus may include to optimize the dialysis efficacy first to reduce serum parathyroid hormone to reduce the amount of phosphorous/calcium. Dry skin can be taken care of by the application of emollients and non-soap cleaners. UVB phototherapy and prescription of some drugs may also be done.

Uremic Pruritus Emerging Drugs Chapters

This segment of the Uremic Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Uremic Pruritus Emerging Drugs

CR845: Cara Therapeutics CR845, also known as KORSUVA, is in the preregistration phase of the drug development process. The drug belongs to the class of kappa opioid receptor agonists to treat the itch associated with uremic pruritus in a new way. KORSUVA IV has shown positive results in phase III trials and the efficacy of the same drug in the tablet form is being tested in the Phase II trial for non-hemodialysis patients.

LT 5001: Lumosa Therpaeutics Lumos Therapeutics’ LT 5001, is a drug candidate for uremic pruritus. The drug has received Taiwan FDA approval for conducting Ib/2 trial. It is being developed to be applied topically. It is a partial mu-opioid antagonist and kappa-opioid agonist. The formulation is thought to have the ability to modulate opioid receptors that are there on immune cells and sensorynerves.

Uremic Pruritus: Therapeutic Assessment

This segment of the report provides insights about the different Uremic Pruritus drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Uremic Pruritus

There are approx. 4+ key companies which are developing the therapies for Uremic Pruritus. The companies which have their Uremic Pruritus drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Cara Therapeutics and others.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Uremic Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uremic Pruritus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uremic Pruritus therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uremic Pruritus drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Uremic Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Uremic Pruritus.

Uremic Pruritus Report Insights

• Uremic Pruritus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uremic Pruritus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Uremic Pruritus drugs?
• How many Uremic Pruritus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uremic Pruritus?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Uremic Pruritus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uremic Pruritus and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cara Therapuetics
• Lumosa Therapeutics

Key Products

• CR845
• LT 5001

This product will be delivered within 2 business days.